Ruthenium(Ii) Polypyridyl Complexes Inhibit Tumor Growth Through Stimulating Immune System to Increase Cd8+ T Cell
Опубликована: Янв. 1, 2025
In
this
work,
we
have
carefully
designed
and
synthesized
two
Ru(II)
metal
complexes:
[Ru(phen)2(HMPIP)](PF6)2
(6a,
where
phen
=
1,10-phenanthroline,
HMPIP
2-(2-hydroxy-3-methylphenyl-1H-imidazo[4,5-f][1,10]phenanthroline)
[Ru(bpy)2(HMPIP)](PF6)2
(6b,
bpy
2,2'-bipyridine).
Using
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide
(MTT)
to
explore
the
cytotoxicity
of
6a
6b
towards
HepG2,
B16,
A549,
SGC-7901,
HCT116
non-cancer
LO2.
The
complexes
exhibited
activity
against
HepG2
cells.
capacity
impede
proliferation
dissemination
cancer
cells
was
evaluated
by
conducting
migration
experiments
3D
model.
anticancer
mechanism
investigated
in
detail.
utilization
cycle
blocking
assays
revealed
that
induced
a
G0/G1
phase
arrest
Apoptosis
examination
proteins
indicated
were
capable
efficiently
inducing
apoptosis
Additionally,
potential
induction
autophagy-mediated
cell
death
explored.
observed
reduction
glutathione
(GSH)
levels
peroxidase
4
(GPX4)
expression
suggested
disruption
redox
homeostasis
within
cells,
an
increment
malondialdehyde
(MDA)
amount,
together
with
BODIPY
staining
experiment,
confirm
can
induce
ferroptosis.
Interestingly,
nude
mouse
model,
showed
significant
suppression
tumor
growth
inhibition
rate
63.4%,
without
causing
any
weight
loss
mice.
studies
on
show
causes
immune
death,
increase
amount
TNF-α
IFN-γ,
reduce
IL-10
content,
which
further
activates
response
CD8+
T
prevent
growth.
Therefore,
inhibits
through
stimulating
These
results
demonstrate
may
be
potent
candidates
for
tumor.
Язык: Английский
Ruthenium(II) Polypyridyl Complexes Inhibit Tumor Growth Through Stimulating Immune System to Increase CD8+ T Cell
Shuang Tian,
Haixin Xu,
Xiaoyu Wu
и другие.
European Journal of Medicinal Chemistry,
Год журнала:
2025,
Номер
289, С. 117470 - 117470
Опубликована: Фев. 28, 2025
Язык: Английский
Low toxicity ginsenoside Rg1-carbon nanodots as a potential therapeutic agent for human non-small cell lung cancer
Colloids and Surfaces B Biointerfaces,
Год журнала:
2024,
Номер
246, С. 114392 - 114392
Опубликована: Ноя. 20, 2024
Язык: Английский
Nanovector approach for co-delivery of Alectinib and hesperidin via inhalational for lung cancer treatment: development, characterization, and preclinical studies
Expert Opinion on Drug Delivery,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 2, 2025
The
current
study
aims
to
fabricate
Nanostructured
Lipid
Carriers
for
the
co-delivery
of
Alectinib
and
Hesperidin
(ALB-HSD
NLC)
non-small
cell
lung
Cancer
(NSCLC)
via
an
inhalational
route.
ALB-HSD
NLC
was
fabricated
using
Melt
emulsification
followed
by
sonication
method
optimized
a
central
composite
design.
formulation
evaluated
various
in
vitro
vivo
studies.
had
satisfactory
results
particle
size,
Zeta
Potential,
PDI,
entrapment
efficiency.
drug
release
more
than
2.5-fold
higher
compared
drugs
suspension
over
72
hr.
A549
human
line
shows
IC50
ALB
HSD,
were
2.289
µg/mL
73.52
µg/mL,
dose-dependent
toxicity
0.0209
μg/mL
0.5213
HSD
Suspension,
respectively,
after
Pharmacokinetic
has
demonstrated
improved
AUC0-t
(1.38,
1.57-fold)
from
suspension.
In
studies
give
significant
on
syngeneic
model.
prepared
could
be
promising
carriers,
they
succeeded
delivering
small
efficient
doses
treat
NSCLC.
Язык: Английский